RS3PE Following Treatment With Combination of Hormonal Therapies Plus Ipilimumab in a Patient With Metastatic Prostate Cancer
Introduction: Immune checkpoint inhibitors (ICIs) are often associated with inflammatory toxicities known as immune-related adverse events (irAEs). Remitting seronegative symmetrical synovitis with pitting edema (RS3PE) is an atypical inflammatory arthritis. Herein, we report a case of RS3PE in a pa...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Innovative Healthcare Institute
2020-08-01
|
| Series: | Journal of Immunotherapy and Precision Oncology |
| Subjects: | |
| Online Access: | https://jipo.org/doi/pdf/10.36401/JIPO-20-2 |
| _version_ | 1828072854899392512 |
|---|---|
| author | Sang T. Kim William A. Murphy Jr Ana Aparicio Sumit K. Subudhi |
| author_facet | Sang T. Kim William A. Murphy Jr Ana Aparicio Sumit K. Subudhi |
| author_sort | Sang T. Kim |
| collection | DOAJ |
| description | Introduction: Immune checkpoint inhibitors (ICIs) are often associated with inflammatory toxicities known as immune-related adverse events (irAEs). Remitting seronegative symmetrical synovitis with pitting edema (RS3PE) is an atypical inflammatory arthritis. Herein, we report a case of RS3PE in a patient with metastatic prostate cancer who was receiving a combination of second-generation hormonal therapies plus ipilimumab. Case Presentation: A 59-year-old man with metastatic prostate cancer developed sudden onset of pain and swelling of the right hand after 15 weeks of treatment with second-generation hormonal therapies plus three cycles of ipilimumab. Symptoms alternated to the left hand. Physical examination showed tender, pitting edema of the left hand with tenderness on the right second through fifth metacarpal phalangeal joints, leading to the diagnosis of RS3PE. Ipilimumab was withheld, and the RS3PE self-resolved; however, 1 month later, the patient had another flare of RS3PE. A bone scan showed active inflammation on bilateral wrists and hands. Methotrexate was initiated, and his symptoms resolved over a few days. Methotrexate was discontinued 2 months later, and RS3PE has been in complete remission. His prostate cancer progressed, and radium-223 treatment was initiated. Conclusion: To the best of our knowledge, this is the first reported case of RS3PE after the combined second-generation hormonal therapy plus ipilimumab. Both rheumatologists and oncologists should be aware that RS3PE can develop as an irAE. Understanding the mechanism of ICI therapy–associated RS3PE is critical to identify predictive biomarkers and develop optimal therapeutic strategies that do not sacrifice antitumor immunity. |
| first_indexed | 2024-04-11T01:17:32Z |
| format | Article |
| id | doaj.art-8a04eb7df57142d08870123cc02d64e1 |
| institution | Directory Open Access Journal |
| issn | 2666-2345 2590-017X |
| language | English |
| last_indexed | 2024-04-11T01:17:32Z |
| publishDate | 2020-08-01 |
| publisher | Innovative Healthcare Institute |
| record_format | Article |
| series | Journal of Immunotherapy and Precision Oncology |
| spelling | doaj.art-8a04eb7df57142d08870123cc02d64e12023-01-03T19:12:44ZengInnovative Healthcare InstituteJournal of Immunotherapy and Precision Oncology2666-23452590-017X2020-08-0112813210.36401/JIPO-20-2i2590-017X-3-3-128RS3PE Following Treatment With Combination of Hormonal Therapies Plus Ipilimumab in a Patient With Metastatic Prostate CancerSang T. Kim0William A. Murphy Jr1Ana Aparicio2Sumit K. Subudhi31 Department of General Internal Medicine, Section of Rheumatology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA2 Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA3 Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA3 Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USAIntroduction: Immune checkpoint inhibitors (ICIs) are often associated with inflammatory toxicities known as immune-related adverse events (irAEs). Remitting seronegative symmetrical synovitis with pitting edema (RS3PE) is an atypical inflammatory arthritis. Herein, we report a case of RS3PE in a patient with metastatic prostate cancer who was receiving a combination of second-generation hormonal therapies plus ipilimumab. Case Presentation: A 59-year-old man with metastatic prostate cancer developed sudden onset of pain and swelling of the right hand after 15 weeks of treatment with second-generation hormonal therapies plus three cycles of ipilimumab. Symptoms alternated to the left hand. Physical examination showed tender, pitting edema of the left hand with tenderness on the right second through fifth metacarpal phalangeal joints, leading to the diagnosis of RS3PE. Ipilimumab was withheld, and the RS3PE self-resolved; however, 1 month later, the patient had another flare of RS3PE. A bone scan showed active inflammation on bilateral wrists and hands. Methotrexate was initiated, and his symptoms resolved over a few days. Methotrexate was discontinued 2 months later, and RS3PE has been in complete remission. His prostate cancer progressed, and radium-223 treatment was initiated. Conclusion: To the best of our knowledge, this is the first reported case of RS3PE after the combined second-generation hormonal therapy plus ipilimumab. Both rheumatologists and oncologists should be aware that RS3PE can develop as an irAE. Understanding the mechanism of ICI therapy–associated RS3PE is critical to identify predictive biomarkers and develop optimal therapeutic strategies that do not sacrifice antitumor immunity.https://jipo.org/doi/pdf/10.36401/JIPO-20-2prostate cancercheckpoint inhibitorsipilimumabimmune-related adverse eventsrs3pe |
| spellingShingle | Sang T. Kim William A. Murphy Jr Ana Aparicio Sumit K. Subudhi RS3PE Following Treatment With Combination of Hormonal Therapies Plus Ipilimumab in a Patient With Metastatic Prostate Cancer Journal of Immunotherapy and Precision Oncology prostate cancer checkpoint inhibitors ipilimumab immune-related adverse events rs3pe |
| title | RS3PE Following Treatment With Combination of Hormonal Therapies Plus Ipilimumab in a Patient With Metastatic Prostate Cancer |
| title_full | RS3PE Following Treatment With Combination of Hormonal Therapies Plus Ipilimumab in a Patient With Metastatic Prostate Cancer |
| title_fullStr | RS3PE Following Treatment With Combination of Hormonal Therapies Plus Ipilimumab in a Patient With Metastatic Prostate Cancer |
| title_full_unstemmed | RS3PE Following Treatment With Combination of Hormonal Therapies Plus Ipilimumab in a Patient With Metastatic Prostate Cancer |
| title_short | RS3PE Following Treatment With Combination of Hormonal Therapies Plus Ipilimumab in a Patient With Metastatic Prostate Cancer |
| title_sort | rs3pe following treatment with combination of hormonal therapies plus ipilimumab in a patient with metastatic prostate cancer |
| topic | prostate cancer checkpoint inhibitors ipilimumab immune-related adverse events rs3pe |
| url | https://jipo.org/doi/pdf/10.36401/JIPO-20-2 |
| work_keys_str_mv | AT sangtkim rs3pefollowingtreatmentwithcombinationofhormonaltherapiesplusipilimumabinapatientwithmetastaticprostatecancer AT williamamurphyjr rs3pefollowingtreatmentwithcombinationofhormonaltherapiesplusipilimumabinapatientwithmetastaticprostatecancer AT anaaparicio rs3pefollowingtreatmentwithcombinationofhormonaltherapiesplusipilimumabinapatientwithmetastaticprostatecancer AT sumitksubudhi rs3pefollowingtreatmentwithcombinationofhormonaltherapiesplusipilimumabinapatientwithmetastaticprostatecancer |